Anti-CD20 and natalizumab in highly active relapsing-remitting multiple sclerosis: the SWIFNA-20 comparative effectiveness studyD. -A. Laplaud,F. Rollot,R. Casey,S. Wiertlewski,J. Pelletier,J. De Seze,P. Labauge,A. Ruet,E. Thouvenot,J. Ciron,P. Clavelou,B. Stankoff,B. Bourre,C. Lebrun-Frenay,E. Maillart,G. Defer,J. -P. Camdessanche,A. Maurousset,K. Hankiewicz,S. Bakchine,A. Montcuquet,S. VukusicMULTIPLE SCLEROSIS JOURNAL（2021）引用 0|浏览24AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
